Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00085150 2015-04-30

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
DermatologicLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT00002765 2015-04-29

Immunotoxin in Treating Patients With Leukemia or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma